Australia · Delayed Price · Currency is AUD Anteris Technologies Global Earnings Call Transcripts
Fiscal Year 2026
-
DurAVR’s development was guided by a disease management approach, resulting in a novel, biomimetic valve with strong anti-calcific properties and superior clinical outcomes. The company targets significant untapped market potential with a proactive launch strategy and aims to justify premium pricing through robust clinical and economic evidence.
-
DurAVR's biomimetic valve platform shows strong clinical performance, including low mean gradients, LV remodeling, and a very low patient-prosthesis mismatch rate. The pivotal PARADIGM trial is set for rapid enrollment, with robust long-term data and high investigator interest.
Fiscal Year 2025
-
The meeting highlighted expanded board expertise, strong clinical and financial progress, and major facility growth to support pivotal trials and commercialization. All proposals were recommended for approval, and management addressed shareholder questions on strategy, capital, and clinical milestones.
-
A new biomimetic TAVR valve with superior hemodynamics is entering a $10B market, aiming to combine the ease of balloon expandable delivery with the clinical benefits of self-expanding valves. With pivotal studies starting soon and strong early data, significant growth and investment opportunities are anticipated.
-
Strong initial OJEMDA launch with broad adoption and $57M in early revenue, supported by a robust cash position and ongoing clinical pipeline progress. Steady growth is expected as market penetration deepens, with significant future opportunities in both relapsed/refractory and frontline settings.
Fiscal Year 2024
-
Anteris option holders met to vote on a scheme to exchange their options for equivalent ATGC options, with the board and an independent expert recommending approval. The meeting proceeded smoothly with no questions raised, and voting results will be announced to the ASX.
-
-
The meeting addressed two resolutions to ratify prior share issues, with poll voting for transparency. No questions were raised by shareholders, and voting results will be released to the ASX. The board reaffirmed its commitment to the company's future.